We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
03/11/2020 07:35 | Rivaldo those estimates seem conservative in a land of 1.4 billion . | carlisle44 | |
03/11/2020 07:33 | Well done ODX. I wonder who might come calling. Chinese market is huge. And this on top of HIV success, RTC, and antibody & antigen testing. No need for a speeding ticket today! Hats off. | carlisle44 | |
03/11/2020 07:30 | Fantastic news.omega has delivered on everything they said they would . Since the strategic review. Just think what can now be achieved with the covid mix as well. | upomega | |
03/11/2020 07:28 | It's worth remembering that Finncap have stated the Chinese market potential is, according to the Chinese distributor, for 1m tests per annum. This implies annual £12m revenues at a 70% gross margin - i.e around £8.4m gross profit per annum. Give that a reasonable multiple and you're talking a substantial portion of the current m/cap. | rivaldo | |
03/11/2020 07:22 | OMEGA have cracked it now big time.........which other UK company have been able to do this in China......none I know of! | swerves1 | |
03/11/2020 07:16 | Very big WELL DONE to Colin and his Ream on Chinese approval for home testing...a big achievement.... | barrywhit | |
03/11/2020 07:12 | No chance. In Trump we Trust! | notknowing | |
03/11/2020 07:09 | Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that the National Medical Products Administration ("NMPA"), formerly the China Food and Drug Administration, has approved the Company's Food Detective(R) test for self-test use in China .Further to the announcement on 2 April 2020 confirming NMPA approval for laboratory use of the Food Detective(R) test in China, Omega's development team has continued to work in conjunction with its distribution partner to support their efforts to achieve NMPA approval to allow the test to be used in people's homes.The Company will support its distribution partner to ensure that Food Detective(R) achieves commercial success in China as an approved home-use test.Colin King, CEO of Omega commented: "I am delighted to receive self-test approval in China which was a key commercial objective for this year. This is another excellent reward for all the hard work put in by both our and our partner's teams in what has remained challenging times around the world."The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014. | fredd1eboy | |
03/11/2020 07:08 | TrumpVirus will be destroyed today. | specialist is the living god | |
03/11/2020 07:05 | Fantastic news. The market for these tests in China must be truly massive! | swerves1 | |
03/11/2020 07:03 | Terrific news - this Chinese approval could be worth a fortune to ODX: "Chinese approval for self-test use of Food Detective(R) test Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that the National Medical Products Administration ("NMPA"), formerly the China Food and Drug Administration, has approved the Company's Food Detective(R) test for self-test use in China . Further to the announcement on 2 April 2020 confirming NMPA approval for laboratory use of the Food Detective(R) test in China, Omega's development team has continued to work in conjunction with its distribution partner to support their efforts to achieve NMPA approval to allow the test to be used in people's homes. The Company will support its distribution partner to ensure that Food Detective(R) achieves commercial success in China as an approved home-use test. Colin King, CEO of Omega commented: "I am delighted to receive self-test approval in China which was a key commercial objective for this year. This is another excellent reward for all the hard work put in by both our and our partner's teams in what has remained challenging times around the world." | rivaldo | |
02/11/2020 23:12 | https://www.theguard | ayl30 | |
02/11/2020 23:07 | All in it together, mass testing of Liverpool using swab test, lamp test, lateral flowBrining in the army to mobilise #ncyt #odx beating this together and return to normality https://twitter.com/ | mcrudden | |
02/11/2020 22:47 | Good post. Hopefully ours will be ready when the pilot results are known "The pilot will help to inform a blueprint for how mass testing can be achieved and how fast and reliable covid-19 testing can be delivered at scale". | coley15 | |
02/11/2020 22:31 | https://twitter.com/ | tomoneyfox | |
02/11/2020 21:39 | “X KING OF TAJ MAHAL” 👑 Specialist I LOVE UR MUMMYS PAUDA (;) (;) MUWAHHH 😘 😘 | riz000 | |
02/11/2020 21:36 | In Trump we Trust! | notknowing | |
02/11/2020 21:29 | “X KING OF TAJ MAHAL” 👑 ODX IS GNA BE MASSIVE IN MATTER OF FEW WEEKS THANK ME LATER 😃😃 | riz000 | |
02/11/2020 21:25 | shorter on fire tomorrow | thehitman1 | |
02/11/2020 21:24 | lateral flow testing mentioned by PM, this will blow tomorrow. | thehitman1 | |
02/11/2020 21:10 | ODX closes at 75p on the way to 20p. No ifs or buts !! | specialist is the living god | |
02/11/2020 21:09 | Monkey 🐒 boy. You donot understand shares or markets. If you be a good monkey we will all buy you some nuts 🥜 hahahahh Hahahhahahah idiot Kebab | specialist is the living god | |
02/11/2020 21:07 | Shut up monkey 🐒 boy. Go back into your tree. Hahahahaha Hahahhahahah 👏👏 | specialist is the living god |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions